Get started
Author

Thibault Gauduchon

Observed names: Coauthor(s) Thibault Gauduchon, T. Gauduchon
OpenAlex ID: A5047459449
PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients
2023 · Thibault Gauduchon, Maria Kfoury, et al. · Gynecologic Oncology · 36
Expanding the molecular spectrum of tenosynovial giant cell tumors
2022 · Thibault Gauduchon, Helene Vanacker, et al. · Frontiers in Oncology · 23
Selpercatinib in the treatment of thyroid cancer
2025 · Thibault Gauduchon, Romain Varnier, et al. · Future Oncology · 4
PDF
Head and neck cancer and immunotherapy: current knowledge and perspective
2019 · Thibault Gauduchon, Thibaut Reverdy, et al. · Journal of Cancer Metastasis and Treatment · 4
Therapeutic perspectives for recurrent or metastatic head and neck squamous cell carcinoma
2025 · Thibault Gauduchon, Eve Marie Neidhardt, et al. · Current Opinion in Oncology · 2
Efficacy of buparlisib according to PIK3CA mutation status in recurrent or metastatic head and neck squamous cell carcinoma: A multicenter phase II trial
2026 · Thibault Gauduchon, Laurence Digue, et al. · Oral Oncology · 1
Patients with medullary thyroid carcinoma and long term treatment with vandetanib: a study from the endocan -tuthyref network
2024 · Helene Lasolle, Livia Lamartina, et al. · Endocrine Abstracts · 1
Response rate with cetuximab used less than 3 months after immunotherapy (IO) for recurrent/metastatic head and neck squamous cell carcinomas (R/M HNSCC) compared to larger delay.
2024 · Yannick Carulla, Eve-Marie Neidhardt, et al. · Journal of Clinical Oncology · 1
HNSCC and Immunotherapy: The Beginning of a Long Story
2019 · Thibault Gauduchon, Thibaut Reverdy, et al. · Journal of Molecular Biomarkers & Diagnosis · 1
PDF
Transformation anaplasique des cancers différenciés de la thyroïde : analyse rétrospective nationale issue du réseau français ENDOCAN-TUTHYREF
2026 · L. Lamartina, J. Hadoux, et al. · Annales d Endocrinologie
PDF
Alkylating agent-based chemotherapy for the treatment of metastatic medullary thyroid cancer: the endocan-tuthyref experience.
2026 · Noemie Simon-Tillaux, Hlne Lasolle, et al. · Endocrine Abstracts
Pharmacological prevention of second primary cancers: From chemoprevention to precision cancer interception
2026 · Mylène Wespiser, Pauline Rochefort, et al. · Cancer Treatment Reviews
OncoMimic peptide-based immunotherapy EO2401 induces shared T cell clusters in patients with adrenal cancer
2026 · Christoph Schultheiß, Brenda Besemer, et al. · Communications Medicine
PDF
Real-world efficacy of cetuximab after immune checkpoint inhibitor and platin failure in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): A 10-year retrospective study in 124 patients.
2026 · Benoît Lecoester, Hugo Greve Viallon, et al. · Journal of Clinical Oncology
Activity of Low Dose Nivolumab in Patients with Advanced Squamous Cell Carcinomas and Other Cancers
2026 · Thibault Gauduchon, Jérôme Fayette, et al. · Preprints.org
PDF
La prise en charge des cancers médullaires de la thyroïde en 2024
2024 · Hélène Lasolle, Françoise Borson-Chazot, et al. · Bulletin du Cancer
Évaluation des patients avec carcinome médullaire thyroïdien en réponse prolongée au vandetanib dans le réseau français ENDOCAN – TUTHYREF
2024 · H. Lasolle, L. Lamartina, et al. · Annales d Endocrinologie
Comparison between exclusive (chemo)radiation and surgery or induction chemotherapy as first curative treatment for localized or locally advanced head and neck squamous cell carcinomas (L(A)-HNSCC): Sub-analysis of the EPOCKS study
2023 · Coauthor(s) Thibault Gauduchon, Cécile Dalban, et al. · Oral Oncology Reports
Works count: 18
Citation count: 73
H-index: 4
I10-index: 2
Year
Topic
Type